ReviewCureus2025
Exploring the Potential of Stem Cells: A Systematic Review on Cellular Therapy for Sensorineural Hearing Loss.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protective Effect of Selegiline (R-deprenyl) in Aminoglycoside-Induced Hearing Loss.Neurochemical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sensorineural hearing loss affects a significant portion of the global population, with its prevalence projected to rise sharply in the coming years. Most cases involve the degeneration of hair cells and spiral ganglion neurons within the inner ear, and current therapeutic options for hearing rehabilitation offer limited efficacy with variable outcomes among patients. This systematic review evaluates the existing evidence on stem cell therapy as an intervention for hearing loss, focusing on its impact on hearing restoration, quality of life, and safety. A thorough search of electronic databases and clinical trial registries identified randomized and quasi-randomized studies on this topic. Eight studies met the inclusion criteria, investigating various types of stem cells such as embryonic, umbilical cord, and inner ear cells administered intravenously or directly into the inner ear. Most studies used animal models to simulate hearing loss, while one was conducted in humans. Findings on hearing improvement were mixed, with some studies reporting significant improvements in hearing thresholds and others showing no effect. The safety of stem cell therapy was assessed in a single human study, which noted no significant adverse effects. While the results indicate potential therapeutic value, further human studies with standardized protocols and larger sample sizes are necessary to clarify the safety and effectiveness of stem cell therapy for sensorineural hearing loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.